NCT03136055View on ClinicalTrials.gov

Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 20, 2017

Primary Completion Date

October 31, 2021

Study Completion Date

October 31, 2021

Conditions
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Interventions
DRUG

Pembrolizumab

Given Intravenously (IV)

DRUG

Irinotecan

Given IV

DRUG

Paclitaxel

Given IV

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Center, New York

94115

University of California, San Francisco, San Francisco

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT03136055 - Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas | Biotech Hunter | Biotech Hunter